Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Objectives</h3><p>The effectiveness of trimethoprim/sulfamethoxazole (TMP/SMZ) for pneumocystis pneumonia (PCP) is limited with adverse events. Caspofungin, by inhibiting the cyst form of <i>Pneumocystis jirovecii</i>, may be an alternative therapy for PCP. However, the availability of clinical data about caspofungin combined with TMP/SMZ in the treatment of PCP in HIV‐infected patients is limited. Thus, we aimed to examine the clinical effectiveness and safety of caspofungin combined with TMP/SMZ as a first‐line therapy for moderate‐to‐severe PCP in HIV‐infected patients. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>From January 2017 to December 2019, data of HIV‐infected patients with moderate‐to‐severe PCP who received either TMP/SMZ alone or caspofungin combined with TMP/SMZ as first‐line therapy were retrospectively reviewed to assess the effectiveness and safety of each regimen. The Kaplan–Meier curve and log‐rank test were used for survival analysis.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>A total of 278 patients met the criteria. The overall positive response rate of PCP treatment was 48.92%, and the overall all‐cause in‐hospital mortality rate was 33.09%. Patients who received combination therapy consisting of caspofungin and TMP/SMZ had a better positive response rate (59.44% <i>vs</i>. 37.78%, <i>P</i> < 0.001) and lower all‐cause in‐hospital mortality rate (24.48% <i>vs</i>. 42.22%, <i>P</i> = 0.003). Also, patients who received combination therapy had higher survival rate during a hospital stay (75.52% <i>vs</i>. 57.78%, <i>P</i> = 0.004), and those who received longer combination therapy were more likely to have higher survival rate (<i>P</i> = 0.042). We found that age (<i>P</i> = 0.019), CD4 cell count (<i>P</i> = 0.001) and therapeutic regimen (<i>P</i> = 0.002) were significant risk factors for all‐cause in‐hospital mortality rate in univariate analysis. In multivariate analysis, only CD4 cell count and therapeutic regimen were statistically significant factors associated with all‐cause in‐hospital mortality rate. Patients with a CD4 count of > 30 cells/µL and patients who received combination therapy consisting of caspofungin and TMP/SMZ were more likely to survive from PCP (<i>P</i> = 0.011 and <i>P</i> = 0.002, respectively). There were no additional severe adverse events caused by adding caspofungin. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>For HIV‐infected patients with moderate‐to‐severe PCP, combination therapy with caspofungin and TMP/SMZ is an effective and promising first‐line therapy with no greater number of adverse events compared with TMP/SMZ monotherapy. Patients who received caspofungin had better positive response rates and lower all‐cause in‐hospital mortality rates. Also, we recommend early initiation of caspofungin.</p></section>

The clinical analysis of the effectiveness of caspofungin for severe pulmonary fungal infection

Clinical analysis of 14 cases of candidemia

Efficacy of Caspofungin Combined with Trimethoprim/sulfamethoxazole As First-Line Therapy to Treat Non-Hiv Patients with Severe Pneumocystis Pneumonia.

Clinical study of caspofungin for the treatment of invasive fungal disease

Caspofungin Treatment for Pulmonary Invasive Fungal Disease in Hematology Patients: A Retrospective Study in A Clinical Practice Setting in China

Efficacy of Caspofungin in Unclassified Invasive Fungal Infection Cases: A Retrospective Analysis of Patients with Hematological Malignancies in China.

Analysis of caspofungin combined with clindamycin for severe pneumocystis pneumonia

Clinical analysis of caspofungin treatment for invasive fungal disease in advanced age patients

[Clinical Study of Amphotericin B in the Treatment of Invasive Fungal Infection in 111 Hematological Disorder Patients with Neutrocytopenia].

Efficacy and Safety of Itraconazole As Empirical Antifungal Therapy in Febrile Neutropenic Patients with Hematologic Malignancies: an Open-Lable, Multicenter, Observational Trial in A Chinese Cohort

Efficacy and Safety of Caspofungin Followed by Itraconazole Oral Solution for Patients with Invasive Fungal Infection

Efficacy and safety of caspofungin for the treatment of invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease

Whole-body physiology-based pharmacokinetics of caspofungin for general patients, intensive care unit patients and hepatic insufficiency patients

Clinical efficacy and safety of caspofungin in treatment of invasive fungal disease in patients with aplastic anemia

Caspofungin combined with TMP/SMZ as a first‐line therapy for moderate‐to‐severe PCP in patients with human immunodeficiency virus infection

Efficacy of caspofungin combined with clindamycin for Pneumocystis jirovecii pneumonia in a systemic lupus erythematosus patient: A case report and literature review.

Caspofungin for treatment of invasive fungal infections after allogeneic hematopoietic stem cell transplantation

Clinical Analysis on 35 Cases of Pulmonary Cryptoccosis

Impact of risk stratification on the duration of caspofungin therapy for invasive fungal disease in acute leukemic patients.

Efficacy of initial caspofungin plus trimethoprim/sulfamethoxazole for severe PCP in patients without human immunodeficiency virus infection

Effectiveness analysis of fluconazole prophylaxis of fungus infection in patients with hematological diseases